Učitavanje...
Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy
BACKGROUND: Ustekinumab is a new immunosuppressive anti-psoriasis agent. The drug targets the p40 subunit of IL-12 and IL-23 and indirectly inhibits cytokine production by Th17 cells. MAIN OBSERVATIONS: We present a case of a 36-year-old male patient with psoriasis, who received ustekinumab therapy,...
Spremljeno u:
| Glavni autori: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Specjalisci Dermatolodzy
2010
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3157804/ https://ncbi.nlm.nih.gov/pubmed/21886740 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3315/jdcr.2010.1041 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|